Daiichi Sankyo submits sNDA for trastuzumab deruxtecan in Japan for HER2 positive metastatic gastric cancer

Daiichi Sankyo submits supplemental new drug application for trastuzumab deruxtecan in Japan for HER2 positive metastatic gastric cancer. (Credit: 272447 from Pixabay)